Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party

Ali Bazarbachi; Myriam Labopin; Giorgia Battipaglia; Azedine Djabali; Jakob Passweg; Gerard Socié; Edouard Forcade; Didier Blaise; Patrice Chevallier; Corentin Orvain; Jan J Cornelissen; William Arcese; Sylvain Chantepie; Khowla Hashaishi; Jean El Cheikh; Michael Medinger; Jordi Esteve; Arnon Nagler; Mohamad Mohty

doi:10.3324/haematol.2018.211615

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party

Haematologica. 2019 Sep;104(9):e398-e401. doi: 10.3324/haematol.2018.211615. Epub 2019 Feb 21.

Authors

Ali Bazarbachi^{1

2}, Myriam Labopin^{3

4

5}, Giorgia Battipaglia^{4

6}, Azedine Djabali^{3

4}, Jakob Passweg⁷, Gerard Socié⁸, Edouard Forcade⁹, Didier Blaise¹⁰, Patrice Chevallier¹¹, Corentin Orvain¹², Jan J Cornelissen¹³, William Arcese¹⁴, Sylvain Chantepie¹⁵, Khowla Hashaishi³, Jean El Cheikh¹⁶, Michael Medinger⁷, Jordi Esteve^{3

17}, Arnon Nagler^{3

18}, Mohamad Mohty^{3

4

5}

Affiliations

¹ Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon bazarbac@aub.edu.lb.
² Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
³ Acute Leukemia Working Party of EBMT, Paris, France.
⁴ Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
⁵ Hôpital Saint Antoine, Université Pierre and Marie Curie, INSERM, UMRs 938, Paris, France.
⁶ Hematology Department, Federico II University of Naples, Naples, Italy.
⁷ University Hospital, Hematology, Basel, Switzerland.
⁸ Hôpital Saint Louis, Department of Hematology - BMT, Paris, France.
⁹ CHU Bordeaux Hôpital Haut-leveque, Pessac, France.
¹⁰ Programme de Transplantation and Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
¹¹ CHU Nantes, Department D'Hematologie, Nantes, France.
¹² CHRU, Service des Maladies du Sang, Angers, France.
¹³ Department of Hematology, Rotterdam, the Netherlands.
¹⁴ Tor Vergata University of Rome, Stem Cell Transplant Unit, Policlinico Universitario Tor Vergata, Rome, Italy.
¹⁵ CHU CAEN, Institut d'Hématologie de Basse-Normandie, Caen, France.
¹⁶ Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
¹⁷ Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
¹⁸ Chaim Sheba Medical Center, Tel-Hashomer, Israel.

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage
Female
Gene Duplication
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Mutation*
Neoplasm Recurrence, Local
Registries
Remission Induction
Retrospective Studies
Salvage Therapy
Sorafenib / administration & dosage*
Transplantation, Homologous
Treatment Outcome
Young Adult
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Antineoplastic Agents
Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3